首页 > 最新文献

Cancer Epidemiology Biomarkers & Prevention最新文献

英文 中文
Breast, Colorectal, and Prostate Cancer Incidence among Filipino Americans by Generational Status in the Multiethnic Cohort Study. 多民族队列研究》中按世代状况分列的美籍菲律宾人乳腺癌、结直肠癌和前列腺癌发病率。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0647
Janine V Abe, Justin Legaspi, Cherie Guillermo, David Bogumil, Veronica Wendy Setiawan, Loïc Le Marchand, Brenda Y Hernandez, Lynne R Wilkens, Gertraud Maskarinec

Background: Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort.

Methods: We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression.

Results: Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer.

Conclusions: In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer.

Impact: Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.

背景:菲律宾裔美国人分别占夏威夷和加利福尼亚州人口的 12% 和 4%,其中很大一部分移民的癌症发病率不断上升。本研究调查了多民族队列(MEC)中不同世代的大肠癌、乳腺癌和前列腺癌发病率:我们分析了 10,495 名菲律宾籍 MEC 第一代、第二代和第三代参与者,其中 26.8% 为混合种族和族裔。通过与全州癌症登记处的链接,发现了 375 例乳腺癌、249 例结直肠癌和 436 例前列腺癌病例。我们使用 Cox 模型来计算世代状况与癌症发病率之间关系的危险比 (HR) 和 95% 置信区间 (CI)。模型根据队列加入时的年龄和基于逐步回归法选择的癌症特异性协变量进行了调整:与第一代相比,第二代和第三代的结直肠癌发病率明显较高,HR 分别为 1.43(95%CI:1.04,1.98)和 1.76(95%CI:1.29,2.38)。在对相关协变量进行调整后,这种关联性有所减弱。即使在完全调整模型中,第三代与第一代的乳腺癌发病率也有所上升(HR=1.29,95%CI:1.01,1.63),而前列腺癌的发病率几乎没有差异:在这项前瞻性研究中,我们发现不同世代的发病率存在差异,特别是男性结直肠癌和女性乳腺癌:影响:了解文化差异导致的行为变化有助于降低流动人口的癌症风险。
{"title":"Breast, Colorectal, and Prostate Cancer Incidence among Filipino Americans by Generational Status in the Multiethnic Cohort Study.","authors":"Janine V Abe, Justin Legaspi, Cherie Guillermo, David Bogumil, Veronica Wendy Setiawan, Loïc Le Marchand, Brenda Y Hernandez, Lynne R Wilkens, Gertraud Maskarinec","doi":"10.1158/1055-9965.EPI-24-0647","DOIUrl":"10.1158/1055-9965.EPI-24-0647","url":null,"abstract":"<p><strong>Background: </strong>Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort.</p><p><strong>Methods: </strong>We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression.</p><p><strong>Results: </strong>Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer.</p><p><strong>Conclusions: </strong>In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer.</p><p><strong>Impact: </strong>Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1311-1317"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Leukocyte DNA Methylation Markers of Periodontal Disease and Risk of Lung Cancer in a Case-Control Study Nested in the CLUE II Cohort. 嵌套于 CLUE II 队列的一项病例对照研究中牙周病和肺癌风险的血白细胞 DNA 甲基化标记。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0279
Rachel Mulvaney, Yongyi Pan, Naisi Zhao, Flavia Teles, Jiayun Lu, Elizabeth A Platz, Karl T Kelsey, Dominique S Michaud

Background: Periodontal disease and DNA methylation markers have separately been associated with lung cancer risk. Examining methylation levels at genomic regions previously linked to periodontal disease may provide insights on the link between periodontal disease and lung cancer.

Methods: In a nested case-control study drawn from the CLUE II cohort, we measured DNA methylation levels in 208 lung cancer cases and 208 controls. We examined the association between 37 DNA-methylated 5'-C-phosphate-G-3' (CpG) sites at three genomic regions, homeobox 4 (HOXA4), zinc finger protein (ZFP57), and a long noncoding RNA gene located in Chr10 (ENSG00000231601), and lung cancer risk.

Results: Statistically significant associations with lung cancer risk were observed for all 14 CpG sites from HOXA4 (OR ranging 1.41-1.62 for 1 SD increase in the DNA methylation level, especially within 15 years) and 1 CpG site on gene ENSG00000231601 (OR = 1.34 for 1 SD increase in the DNA methylation level). Although CpG sites on gene ZFP57 were not associated with lung cancer risk overall, statistically significant inverse associations were noted for six CpG sites when restricting follow-up to 15 years (OR = 0.73-0.77 for 1 SD increase in the DNA methylation level).

Conclusions: Key methylation levels associated with periodontal disease are also associated with lung cancer risk. For both HOXA4 and ZFP57, the associations were stronger within 15 years of follow-up, which suggest that, if causal, the impact of methylation is acting late in the natural history of lung cancer.

Impact: Identifying biological pathways that link periodontal disease and lung cancer could provide new opportunities for lung cancer detection and prevention.

背景:牙周病和DNA甲基化标记分别与肺癌风险有关。研究以前与牙周病相关的基因组区域的甲基化水平,可能有助于深入了解牙周病与肺癌之间的联系:在一项来自 CLUE II 队列的嵌套病例对照研究中,我们测量了 208 例肺癌病例和 208 例对照组的 DNA 甲基化水平。我们检测了三个基因组区域(Homeobox 4 (HOXA4)、锌指蛋白 (ZFP57) 和位于 Chr10 (ENSG00000231601)的 lcRNA 基因区域)的 37 个 DNA 甲基化 CpG 位点与肺癌风险之间的关联:HOXA4的所有14个CpG位点(甲基化水平每增加1 SD,几率比[OR]为1.41-1.62,尤其是在15年内)和基因ENSG00000231601的一个CpG位点(DNA甲基化水平每增加1 SD,几率比=1.34)都与肺癌风险有统计学意义。虽然基因 ZFP57 上的 CpG 位点总体上与肺癌风险无关,但如果将随访时间限制在 15 年,则有 6 个 CpGs 存在统计学意义上的显著反向关联(甲基化水平每增加 1 SD,OR=0.73-0.77):结论:与牙周病相关的关键甲基化变化也与肺癌风险有关。结论:与牙周病相关的关键甲基化变化也与肺癌风险有关。对于HOXA4和ZFP57,这些关联在15年的随访中更为强烈,这表明它们在肺癌自然史中起作用的时间较晚:影响:确定将牙周病与肺癌联系起来的生物学途径可为肺癌的检测和预防提供新的机会。
{"title":"Blood Leukocyte DNA Methylation Markers of Periodontal Disease and Risk of Lung Cancer in a Case-Control Study Nested in the CLUE II Cohort.","authors":"Rachel Mulvaney, Yongyi Pan, Naisi Zhao, Flavia Teles, Jiayun Lu, Elizabeth A Platz, Karl T Kelsey, Dominique S Michaud","doi":"10.1158/1055-9965.EPI-24-0279","DOIUrl":"10.1158/1055-9965.EPI-24-0279","url":null,"abstract":"<p><strong>Background: </strong>Periodontal disease and DNA methylation markers have separately been associated with lung cancer risk. Examining methylation levels at genomic regions previously linked to periodontal disease may provide insights on the link between periodontal disease and lung cancer.</p><p><strong>Methods: </strong>In a nested case-control study drawn from the CLUE II cohort, we measured DNA methylation levels in 208 lung cancer cases and 208 controls. We examined the association between 37 DNA-methylated 5'-C-phosphate-G-3' (CpG) sites at three genomic regions, homeobox 4 (HOXA4), zinc finger protein (ZFP57), and a long noncoding RNA gene located in Chr10 (ENSG00000231601), and lung cancer risk.</p><p><strong>Results: </strong>Statistically significant associations with lung cancer risk were observed for all 14 CpG sites from HOXA4 (OR ranging 1.41-1.62 for 1 SD increase in the DNA methylation level, especially within 15 years) and 1 CpG site on gene ENSG00000231601 (OR = 1.34 for 1 SD increase in the DNA methylation level). Although CpG sites on gene ZFP57 were not associated with lung cancer risk overall, statistically significant inverse associations were noted for six CpG sites when restricting follow-up to 15 years (OR = 0.73-0.77 for 1 SD increase in the DNA methylation level).</p><p><strong>Conclusions: </strong>Key methylation levels associated with periodontal disease are also associated with lung cancer risk. For both HOXA4 and ZFP57, the associations were stronger within 15 years of follow-up, which suggest that, if causal, the impact of methylation is acting late in the natural history of lung cancer.</p><p><strong>Impact: </strong>Identifying biological pathways that link periodontal disease and lung cancer could provide new opportunities for lung cancer detection and prevention.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1339-1346"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study. 接受曲妥珠单抗治疗的 HER2+ 乳腺癌患者的社会人口差异:一项基于英国人口的研究。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0144
Ruth P Norris, Rosie Dew, Alastair Greystoke, Nicola Cresti, Henry Cain, Adam Todd, Linda Sharp

Background: Sociodemographic disparities in traditional breast cancer treatment receipt in nonpublicly funded healthcare systems are well documented. This study investigated trastuzumab receipt by sociodemographic factors within a female, HER2+ breast cancer population in England's publicly funded National Health Service.

Methods: The English national population-based cancer registry and linked Systemic Anti-Cancer Therapy database identified 36,985 women with HER2+ invasive breast cancer diagnosed between January 1, 2012 and December 31, 2017. Multivariable logistic regression determined the likelihood of trastuzumab receipt in early and metastatic disease by the deprivation category of area of residence and other sociodemographic characteristics.

Results: Early-stage trastuzumab receipt followed a socioeconomic gradient. Women residing in the most deprived areas were 10% less likely to receive trastuzumab [multivariable OR 0.90; 95% confidence interval (CI), 0.83-0.98] compared with women residing in the least deprived areas. In both early and metastatic disease, trastuzumab receipt was less likely in older women with more comorbidities, estrogen receptor-positive disease, and who were not discussed at a multidisciplinary team meeting.

Conclusions: Despite the provision of free care at the point of delivery in England, sociodemographic disparities in early-stage HER2+ trastuzumab receipt occur. Further research determining how inequities contribute to disparities in outcomes is warranted to ensure optimized trastuzumab use for all.

Impact: Fair access to novel cancer treatments regardless of place of residence, sociodemographic characteristics, and/or cancer stage requires prioritization in future cancer improvement policies. See related In the Spotlight, p. 1259.

背景:在非公费医疗系统中,接受传统乳腺癌治疗的社会人口统计学差异已被充分记录。本研究调查了英国公费国民医疗服务体系中女性 HER2+ 乳腺癌患者接受曲妥珠单抗治疗的社会人口因素:英国国家人口癌症登记处和链接的系统抗癌疗法(SACT)数据库确定了 36,985 名于 2012 年 1 月 1 日至 2017 年 12 月 31 日确诊的 HER2+ 侵袭性乳腺癌女性患者。多变量逻辑回归确定了在(i)早期和(ii)转移性疾病中接受曲妥珠单抗治疗的可能性,并按居住地的贫困类别和其他社会人口特征进行了分类:结果:早期患者接受曲妥珠单抗治疗的几率呈社会经济梯度分布。与居住在最贫困地区的妇女相比,居住在最贫困地区的妇女接受曲妥珠单抗治疗的可能性要低10%(多变量OR为0.90,(95% CI)为0.83,0.98)。在早期和转移性疾病中,合并症较多、ER阳性以及未在多学科小组会议上讨论过的老年妇女接受曲妥珠单抗治疗的可能性较低:尽管英格兰提供免费的分娩护理,但在早期HER2+曲妥珠单抗的接受方面仍存在社会人口差异。为确保所有人都能优化使用曲妥珠单抗,有必要开展进一步研究,确定不平等是如何导致结果差异的:无论居住地、社会人口特征和/或癌症分期如何,都应公平获得新型癌症治疗方法,这需要在未来的癌症改善政策中予以优先考虑。
{"title":"Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study.","authors":"Ruth P Norris, Rosie Dew, Alastair Greystoke, Nicola Cresti, Henry Cain, Adam Todd, Linda Sharp","doi":"10.1158/1055-9965.EPI-24-0144","DOIUrl":"10.1158/1055-9965.EPI-24-0144","url":null,"abstract":"<p><strong>Background: </strong>Sociodemographic disparities in traditional breast cancer treatment receipt in nonpublicly funded healthcare systems are well documented. This study investigated trastuzumab receipt by sociodemographic factors within a female, HER2+ breast cancer population in England's publicly funded National Health Service.</p><p><strong>Methods: </strong>The English national population-based cancer registry and linked Systemic Anti-Cancer Therapy database identified 36,985 women with HER2+ invasive breast cancer diagnosed between January 1, 2012 and December 31, 2017. Multivariable logistic regression determined the likelihood of trastuzumab receipt in early and metastatic disease by the deprivation category of area of residence and other sociodemographic characteristics.</p><p><strong>Results: </strong>Early-stage trastuzumab receipt followed a socioeconomic gradient. Women residing in the most deprived areas were 10% less likely to receive trastuzumab [multivariable OR 0.90; 95% confidence interval (CI), 0.83-0.98] compared with women residing in the least deprived areas. In both early and metastatic disease, trastuzumab receipt was less likely in older women with more comorbidities, estrogen receptor-positive disease, and who were not discussed at a multidisciplinary team meeting.</p><p><strong>Conclusions: </strong>Despite the provision of free care at the point of delivery in England, sociodemographic disparities in early-stage HER2+ trastuzumab receipt occur. Further research determining how inequities contribute to disparities in outcomes is warranted to ensure optimized trastuzumab use for all.</p><p><strong>Impact: </strong>Fair access to novel cancer treatments regardless of place of residence, sociodemographic characteristics, and/or cancer stage requires prioritization in future cancer improvement policies. See related In the Spotlight, p. 1259.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1298-1310"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer. 与 I-IIIA 期乳腺癌女性患者非指南化疗相关的患者特征。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0360
Jenna Bhimani, Kelli O'Connell, Sonia Persaud, Victoria Blinder, Rachael P Burganowski-Doud, Isaac J Ergas, Grace B Gallagher, Jennifer J Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke, Cecile A Laurent, Raymond Liu, Kanichi G Nakata, Donna R Rivera, Janise M Roh, Sara Tabatabai, Emily Valice, Elisa V Bandera, Erin J Aiello Bowles, Lawrence H Kushi, Elizabeth D Kantor

Background: Guidelines informing chemotherapy regimen selection are based on clinical trials with participants who do not necessarily represent general populations with breast cancer. Understanding who receives nonguideline regimens is important for understanding real-world chemotherapy administration and how it relates to patient outcomes.

Methods: Using data from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study, based at Kaiser Permanente Northern California (2006-2019) and Kaiser Permanente Washington (2004-2015), we use logistic regression to examine the associations between patient characteristics and receipt of nonguideline chemotherapy regimens among 11,293 women with primary stage I to IIIA breast cancer receiving chemotherapy.

Results: The use of nonguideline regimens was strongly associated with several factors, including older age [≥80 vs. 18-39 years: OR, 5.25; 95% confidence interval (CI), 3.06-9.00; P-trend = 0.002] and HER2 status (HER2+ vs. HER2-: OR, 3.44; 95% CI, 3.06-3.87) and was less likely in women with larger tumor size (>5 cm vs. 0.1 to ≤0.5 cm: OR, 0.56; 95% CI, 0.36-0.87; P-trend = 0.01) and diagnosed in later years (2012-2019 vs. 2005-2011: OR, 0.80; 95% CI, 0.71-0.90). Factors associated varied by type of nonguideline regimens. For example, women with comorbidity and older age were more likely to receive nonguideline drug combinations in particular, whereas women with larger tumor size were less likely to receive nonguideline administration schedules.

Conclusions: Nonguideline chemotherapy regimens are more likely in certain patient populations.

Impact: These associations highlight that vulnerable patient populations may be less likely to receive guideline care, and thus, real-world studies are essential for understanding how the use of nonguideline regimens impacts patient outcomes in these groups.

背景:化疗方案选择指南以临床试验为基础,而临床试验的参与者并不一定代表乳腺癌患者的总体情况。了解哪些患者接受了非指南方案对于了解现实世界中的化疗管理及其与患者预后的关系非常重要:利用北加州凯泽医疗集团(Kaiser Permanente Northern California,2006-2019 年)和华盛顿凯泽医疗集团(Kaiser Permanente Washington,2004-2015 年)的最佳乳腺癌化疗剂量(Optimal Breast Cancer Chemotherapy Dosing,OBCD)队列研究的数据,我们使用逻辑回归法研究了 11,293 名接受化疗的 I-IIIA 期原发性乳腺癌女性患者中,患者特征与接受非 NCCN 指南化疗之间的关联:结果:非指南方案的使用与几个因素密切相关,包括年龄较大(OR≥80 vs 18-39:5.25,95%CI:3.06-9.00)(p-trend=0.002)和人类表皮生长因子-2状态(ORHER2+ vs HER2-:3.44;95%CI:3.06-3.87),且肿瘤尺寸较大(OR>5cm vs 0.1-≤0.5cm:0.56;95%CI:0.36-0.87)(P-趋势=0.01)和确诊时间较晚(OR2012-2019 vs 2005-2011:0.80;95%CI:0.71-0.90)的女性患病几率较低。相关因素因非指南方案的类型而异。例如,患有合并症和年龄较大的女性接受非指南药物组合的可能性更大,而肿瘤体积较大的女性接受非指南给药方案的可能性较小:结论:某些患者更有可能接受非指南化疗方案:影响:这些关联凸显了弱势患者群体可能较少接受指南护理,因此真实世界研究对于了解非指南方案的使用如何影响这些群体的患者预后至关重要。
{"title":"Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer.","authors":"Jenna Bhimani, Kelli O'Connell, Sonia Persaud, Victoria Blinder, Rachael P Burganowski-Doud, Isaac J Ergas, Grace B Gallagher, Jennifer J Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke, Cecile A Laurent, Raymond Liu, Kanichi G Nakata, Donna R Rivera, Janise M Roh, Sara Tabatabai, Emily Valice, Elisa V Bandera, Erin J Aiello Bowles, Lawrence H Kushi, Elizabeth D Kantor","doi":"10.1158/1055-9965.EPI-24-0360","DOIUrl":"10.1158/1055-9965.EPI-24-0360","url":null,"abstract":"<p><strong>Background: </strong>Guidelines informing chemotherapy regimen selection are based on clinical trials with participants who do not necessarily represent general populations with breast cancer. Understanding who receives nonguideline regimens is important for understanding real-world chemotherapy administration and how it relates to patient outcomes.</p><p><strong>Methods: </strong>Using data from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study, based at Kaiser Permanente Northern California (2006-2019) and Kaiser Permanente Washington (2004-2015), we use logistic regression to examine the associations between patient characteristics and receipt of nonguideline chemotherapy regimens among 11,293 women with primary stage I to IIIA breast cancer receiving chemotherapy.</p><p><strong>Results: </strong>The use of nonguideline regimens was strongly associated with several factors, including older age [≥80 vs. 18-39 years: OR, 5.25; 95% confidence interval (CI), 3.06-9.00; P-trend = 0.002] and HER2 status (HER2+ vs. HER2-: OR, 3.44; 95% CI, 3.06-3.87) and was less likely in women with larger tumor size (>5 cm vs. 0.1 to ≤0.5 cm: OR, 0.56; 95% CI, 0.36-0.87; P-trend = 0.01) and diagnosed in later years (2012-2019 vs. 2005-2011: OR, 0.80; 95% CI, 0.71-0.90). Factors associated varied by type of nonguideline regimens. For example, women with comorbidity and older age were more likely to receive nonguideline drug combinations in particular, whereas women with larger tumor size were less likely to receive nonguideline administration schedules.</p><p><strong>Conclusions: </strong>Nonguideline chemotherapy regimens are more likely in certain patient populations.</p><p><strong>Impact: </strong>These associations highlight that vulnerable patient populations may be less likely to receive guideline care, and thus, real-world studies are essential for understanding how the use of nonguideline regimens impacts patient outcomes in these groups.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1286-1297"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sociodemographic and Socioeconomic Factors Correlate with Late-Stage Pediatric Hodgkin Lymphoma and Rhabdomyosarcoma: A Report from the Children's Oncology Group Registries. 社会人口因素与晚期小儿霍奇金淋巴瘤和横纹肌肉瘤的关系:儿童肿瘤学组登记报告》。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0510
Judy Y Ou, Heydon K Kaddas, Todd A Alonzo, Logan G Spector, Negar Fallahazad, Emily Owens, Lindsay J Collin, Adam L Green, Anne C Kirchhoff

Background: We examined the association between late-stage diagnosis and individual- and community-level sociodemographic and socioeconomic characteristics among patients with pediatric Hodgkin lymphoma and rhabdomyosarcoma (RMS).

Methods: We obtained Children's Oncology Group data from 1999 to 2021 including summary stage [local (L), regional (R), and distant (D)], tumor subtype, demographics, and ZIP Code at diagnosis. We linked ZIP Codes to county-level redlining scores (C, D = greatest redlining), the Child Opportunity Index, and measures of segregation (racial dissimilarity indices). Logistic regressions calculated odds ratios for late-stage diagnosis and by race within tumor subtype.

Results: In total, 5,956 patients with Hodgkin lymphoma and 2,800 patients with RMS were included. Late-stage diagnosis of Hodgkin lymphoma was correlated with Black race [ORDistant(D) vs. regional/local (R&L) = 1.38 (1.13-1.68)], being uninsured [ORD vs. R&L = 1.38 (1.09-1.75)], and subtype [nodular sclerosis vs. Other Hodgkin lymphoma: ORD vs. R&L = 1.64 (1.34-2.01), Untyped: ORD vs. R&L = 1.30 (1.04-1.63)]. Late-stage RMS was correlated with bilingual households [ORDistant/regional(D&R) vs. local(L) = 2.66 (1.03-6.91)] and tumor type [alveolar vs. embryonal ORD vs. R&L = 6.16 (5.00-7.58)]. Community-level factors associated with late-stage Hodgkin lymphoma were greater Black (OR80-100% = 1.83; 95% CI = 1.11-3.02) and Hispanic (OR60-79% = 1.30; 95% CI = 1.05-1.60) dissimilarity indices. Late-stage diagnosis for RMS was associated with more redlined census tracts within counties (OR = 1.54; 95% CI = 1.02-2.35) and low/very low Child Opportunity Index (OR = 1.21; 95% CI = 1.02-1.45).

Conclusions: Novel markers of community deprivation, such as redlining and racial segregation, were correlated with cancer outcomes for children with Hodgkin lymphoma and RMS in this first disparities study using Children's Oncology Group registries.

Impact: The interplay of multilevel risk factors provides important consideration for efforts to improve early detection of pediatric cancer diagnosis.

背景:我们研究了小儿霍奇金淋巴瘤(HL)和横纹肌肉瘤(RMS)患者晚期诊断与个人和社区特征之间的关系:我们研究了小儿霍奇金淋巴瘤(HL)和横纹肌肉瘤(RMS)患者的晚期诊断与个人和社区特征之间的关系:我们获得了儿童肿瘤学组(Children's Oncology Group,COG)1999-2021 年的数据,包括诊断时的简要分期(局部分期(L)、区域分期(R)、远处分期(D))、肿瘤亚型、人口统计学特征和邮政编码。我们将邮政编码与县级红线分数(C,D=最大红线)、儿童机会指数(COI)和种族隔离度量(种族差异指数(DI))联系起来。逻辑回归计算了晚期诊断的几率比,以及肿瘤亚型中的种族几率比:结果:共纳入 5,933 例 HL 和 2,800 例 RMS 患者。HL的晚期诊断与黑人种族(ORDistant(D) vs regional/local(R&L)=1.38 [1.13-1.68])、无保险(ORD vs R&L=1.38 [1.09-1.75])和亚型(结节性硬化 vs 其他HL:ORD vs R&L=1.64 [1.34-2.01],未分型:ORD vs R&L=1.30[1.04-1.63])。晚期横纹肌肉瘤与双语家庭(ORDistant/ regional(D&R) vs local(L)=2.66 [1.03-6.91])和肿瘤类型(肺泡型 vs 胚胎型 ORD vs R&L=6.16 [5.00-7.58])相关。与晚期HL相关的社区因素是黑人(OR80-100%=1.83;95%CI=1.11-3.02)和西班牙裔(OR60-79%=1.30;95%CI=1.05-1.60)DI较高。晚期RMS诊断与县内更多的红线人口普查区(OR=1.54;95% CI=1.02-2.35)和低/极低COI(OR=1.21;95% CI=1.02-1.45)有关:结论:在这项首次使用COG登记进行的差异研究中,社区贫困的新标志物(如红线和种族隔离)可能会影响HL和RMS患儿的癌症预后:影响:多层次风险因素的相互作用为改善儿科癌症诊断的早期发现提供了重要的考虑因素。
{"title":"Sociodemographic and Socioeconomic Factors Correlate with Late-Stage Pediatric Hodgkin Lymphoma and Rhabdomyosarcoma: A Report from the Children's Oncology Group Registries.","authors":"Judy Y Ou, Heydon K Kaddas, Todd A Alonzo, Logan G Spector, Negar Fallahazad, Emily Owens, Lindsay J Collin, Adam L Green, Anne C Kirchhoff","doi":"10.1158/1055-9965.EPI-24-0510","DOIUrl":"10.1158/1055-9965.EPI-24-0510","url":null,"abstract":"<p><strong>Background: </strong>We examined the association between late-stage diagnosis and individual- and community-level sociodemographic and socioeconomic characteristics among patients with pediatric Hodgkin lymphoma and rhabdomyosarcoma (RMS).</p><p><strong>Methods: </strong>We obtained Children's Oncology Group data from 1999 to 2021 including summary stage [local (L), regional (R), and distant (D)], tumor subtype, demographics, and ZIP Code at diagnosis. We linked ZIP Codes to county-level redlining scores (C, D = greatest redlining), the Child Opportunity Index, and measures of segregation (racial dissimilarity indices). Logistic regressions calculated odds ratios for late-stage diagnosis and by race within tumor subtype.</p><p><strong>Results: </strong>In total, 5,956 patients with Hodgkin lymphoma and 2,800 patients with RMS were included. Late-stage diagnosis of Hodgkin lymphoma was correlated with Black race [ORDistant(D) vs. regional/local (R&L) = 1.38 (1.13-1.68)], being uninsured [ORD vs. R&L = 1.38 (1.09-1.75)], and subtype [nodular sclerosis vs. Other Hodgkin lymphoma: ORD vs. R&L = 1.64 (1.34-2.01), Untyped: ORD vs. R&L = 1.30 (1.04-1.63)]. Late-stage RMS was correlated with bilingual households [ORDistant/regional(D&R) vs. local(L) = 2.66 (1.03-6.91)] and tumor type [alveolar vs. embryonal ORD vs. R&L = 6.16 (5.00-7.58)]. Community-level factors associated with late-stage Hodgkin lymphoma were greater Black (OR80-100% = 1.83; 95% CI = 1.11-3.02) and Hispanic (OR60-79% = 1.30; 95% CI = 1.05-1.60) dissimilarity indices. Late-stage diagnosis for RMS was associated with more redlined census tracts within counties (OR = 1.54; 95% CI = 1.02-2.35) and low/very low Child Opportunity Index (OR = 1.21; 95% CI = 1.02-1.45).</p><p><strong>Conclusions: </strong>Novel markers of community deprivation, such as redlining and racial segregation, were correlated with cancer outcomes for children with Hodgkin lymphoma and RMS in this first disparities study using Children's Oncology Group registries.</p><p><strong>Impact: </strong>The interplay of multilevel risk factors provides important consideration for efforts to improve early detection of pediatric cancer diagnosis.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1327-1338"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adiposity throughout Adulthood and Risk of Young Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study. 年轻女性健康史研究》中成年后的肥胖与年轻乳腺癌肿瘤亚型的风险。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-1067
Lydia Marcus Post, Dorothy R Pathak, Ann S Hamilton, Kelly A Hirko, Richard T Houang, Emily H Guseman, Dan Sanfelippo, Nicole Bohme Carnegie, L Karl Olson, Hallgeir Rui, Ann G Schwartz, Ellen M Velie

Background: The role of adult adiposity in young-onset breast cancer (YOBC) subtype risk is not well understood.

Methods: In this population-based case(n=1812)-control(n=1381) study of invasive YOBC (aged <50 years), cases were identified from the Los Angeles County and Metropolitan Detroit SEER registries, 2010-2015. Area-based, frequency-matched controls were sampled from the 2010 Census. General adiposity (body mass index (BMI)) and central adiposity (waist circumference (WC), waist-to-height ratio (WHtR)) across adulthood and covariates were collected from in-person interviews and measurements. Odds ratios (ORs) and 95% confidence intervals (CIs) for adiposity and YOBC tumor subtypes (i.e., luminal A, luminal B, HER2+, triple negative (TN)) were calculated, overall and by parity, using multivariable weighted logistic regression.

Results: Obese young adult BMI was inversely associated with luminal A YOBC (OR=0.35, 95% CI 0.16-0.79); other subtype associations were non-significant. Similarly, adult overweight and obese BMIs were inversely associated with luminal A (respectively OR=0.66, 95% CI 0.48-0.91 and OR=0.59, 95% CI 0.46-0.87), but not other subtypes. Conversely, larger WC was associated with higher odds of luminal B and TN YOBC (respectively OR=1.48, 95% CI 1.01-2.15 and OR=2.48, 95% CI 1.52-3.88), but not other subtypes (with similar results for WHtR); highest odds were among parous women.

Conclusions: Findings show greater general adult adiposity is associated with reduced odds of luminal A YOBC, while greater central adiposity is associated with increased odds of luminal B and TN YOBC, particularly among parous women.

Impact: Additional studies of central adiposity and YOBC subtype risk, especially incorporating pregnancy history, are warranted.

背景:成人脂肪在年轻乳腺癌(YOBC)亚型风险中的作用尚不清楚:成人脂肪在年轻乳腺癌(YOBC)亚型风险中的作用尚不十分清楚:在这项以人群为基础的病例(1812 例)-对照(1381 例)研究中,研究对象为浸润性 YOBC(年龄:20 岁 结果:肥胖的年轻成人 BMI 与管腔 A 型 YOBC 成反比:肥胖的年轻成人体重指数与管腔A型YOBC成反比(OR=0.35,95% CI 0.16-0.79);其他亚型的相关性不显著。同样,成人超重和肥胖的体重指数与管腔 A 成反比(分别为 OR=0.66,95% CI 0.48-0.91 和 OR=0.59,95% CI 0.46-0.87),但与其他亚型无关。相反,较大的腹围与较高的管腔B型和TN型YOBC几率相关(分别为OR=1.48,95% CI 1.01-2.15和OR=2.48,95% CI 1.52-3.88),但与其他亚型无关(WHtR的结果类似);奇数女性的几率最高:结论:研究结果表明,成人总体脂肪过多与管腔A型YOBC几率降低有关,而中心脂肪过多与管腔B型和TN型YOBC几率增加有关,特别是在奇偶女性中:影响:有必要对中心脂肪率和 YOBC 亚型风险进行更多研究,尤其是结合妊娠史。
{"title":"Adiposity throughout Adulthood and Risk of Young Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study.","authors":"Lydia Marcus Post, Dorothy R Pathak, Ann S Hamilton, Kelly A Hirko, Richard T Houang, Emily H Guseman, Dan Sanfelippo, Nicole Bohme Carnegie, L Karl Olson, Hallgeir Rui, Ann G Schwartz, Ellen M Velie","doi":"10.1158/1055-9965.EPI-24-1067","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1067","url":null,"abstract":"<p><strong>Background: </strong>The role of adult adiposity in young-onset breast cancer (YOBC) subtype risk is not well understood.</p><p><strong>Methods: </strong>In this population-based case(n=1812)-control(n=1381) study of invasive YOBC (aged <50 years), cases were identified from the Los Angeles County and Metropolitan Detroit SEER registries, 2010-2015. Area-based, frequency-matched controls were sampled from the 2010 Census. General adiposity (body mass index (BMI)) and central adiposity (waist circumference (WC), waist-to-height ratio (WHtR)) across adulthood and covariates were collected from in-person interviews and measurements. Odds ratios (ORs) and 95% confidence intervals (CIs) for adiposity and YOBC tumor subtypes (i.e., luminal A, luminal B, HER2+, triple negative (TN)) were calculated, overall and by parity, using multivariable weighted logistic regression.</p><p><strong>Results: </strong>Obese young adult BMI was inversely associated with luminal A YOBC (OR=0.35, 95% CI 0.16-0.79); other subtype associations were non-significant. Similarly, adult overweight and obese BMIs were inversely associated with luminal A (respectively OR=0.66, 95% CI 0.48-0.91 and OR=0.59, 95% CI 0.46-0.87), but not other subtypes. Conversely, larger WC was associated with higher odds of luminal B and TN YOBC (respectively OR=1.48, 95% CI 1.01-2.15 and OR=2.48, 95% CI 1.52-3.88), but not other subtypes (with similar results for WHtR); highest odds were among parous women.</p><p><strong>Conclusions: </strong>Findings show greater general adult adiposity is associated with reduced odds of luminal A YOBC, while greater central adiposity is associated with increased odds of luminal B and TN YOBC, particularly among parous women.</p><p><strong>Impact: </strong>Additional studies of central adiposity and YOBC subtype risk, especially incorporating pregnancy history, are warranted.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma. 骨骼肌和内脏脂肪组织的放射密度是透明细胞肾细胞癌的预后因素。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0306
Patrick T Bradshaw, Linnea T Olsson, Alejandro Sanchez, Andrea Knezevic, Oguz Akin, Jessica M Scott, A Ari Hakimi, Paul Russo, Bette J Caan, Marina Mourtzakis, Helena Furberg

Background: Body composition may be related to survival in patients with clear-cell renal cell carcinoma (ccRCC), but studies have not simultaneously considered adipose and muscle tissue quantity and radiodensity.

Methods: We analyzed data from 1,022 patients with ccRCC who underwent nephrectomy between 2000 and 2020 at Memorial Sloan Kettering Cancer Center. Skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue indexes (cm2/m2) and radiodensities [Hounsfield units (HU)] were assessed from noncontrast presurgical CT scans; clinical and demographic characteristics were available from the time of surgery. HRs and confidence intervals were estimated for overall (OS) and disease-free survival (DFS) through March 2023 in multivariable models that simultaneously accounted for all body composition measures.

Results: The median age of the patients was 58 years, 69% were male, and 90% were White. There were 169 OS events over 8,392 person-years and 253 DFS events over 7,753 person-years of follow-up. In adjusted analyses, poor OS was associated with lower skeletal muscle radiodensity [-10 HU, HR (95% confidence interval), 1.37 (1.05-1.77)] and greater visceral adipose tissue radiodensity [+10 HU, 1.66 (1.06-2.59)], with similar findings for DFS. Poor survival was also associated with greater visceral adipose tissue index [+40 cm2/m2, OS: 1.32 (0.97, 1.79); DFS: 1.33 (1.04, 1.71)]. Associations with skeletal muscle radiodensity were limited to patients with stage 1/2 disease.

Conclusions: Radiodensities of skeletal muscle and visceral adipose tissues may be novel presurgical prognostic factors for patients with ccRCC.

Impact: The findings underscore the importance of evaluating the full range of body composition features simultaneously in multivariable models.

背景:身体成分可能与透明细胞肾细胞癌(ccRCC)患者的存活率有关,但研究并未同时考虑脂肪和肌肉组织的数量以及放射密度:身体成分可能与透明细胞肾细胞癌(ccRCC)患者的存活率有关,但研究并未同时考虑脂肪和肌肉组织的数量及放射密度:我们分析了2000-2020年间在纪念斯隆-凯特琳癌症中心接受肾切除术的1022名ccRCC患者的数据。骨骼肌、内脏脂肪和皮下脂肪组织指数(SMI、VATI、SATI,分别为 cm2/m2)和放射密度(SMD、VATD、SATD,分别为 Hounsfield Units [HU])通过手术前的非对比计算机断层扫描进行评估;临床和人口统计学特征可在手术时获得。在同时考虑所有身体成分指标的多变量模型中,估算了到2023年3月的总生存期(OS)和无病生存期(DFS)的危险比(HR)和置信区间(CI):中位年龄为 58 岁,69% 为男性,90% 为白人。在8392人年的随访过程中发生了169起OS事件,在7753人年的随访过程中发生了253起DFS事件。在调整分析中,较差的 OS 与较低的 SMD(-10 HU,HR (95% CI):1.37 [1.05, 1.77])和较大的 VATD(+10 HU:1.66 [1.06, 2.59])相关,DFS 也有类似的结果。生存率差也与VATI越大有关(+40 cm2/m2,OS:1.32 [0.97,1.79];DFS:1.33 [1.04,1.71])。与SMD的关系仅限于1/2期患者:结论:骨骼肌和内脏脂肪组织的放射性密度可能是ccRCC患者手术前预后的新因素:影响:研究结果强调了在多变量模型中同时评估各种身体成分特征的重要性。
{"title":"Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma.","authors":"Patrick T Bradshaw, Linnea T Olsson, Alejandro Sanchez, Andrea Knezevic, Oguz Akin, Jessica M Scott, A Ari Hakimi, Paul Russo, Bette J Caan, Marina Mourtzakis, Helena Furberg","doi":"10.1158/1055-9965.EPI-24-0306","DOIUrl":"10.1158/1055-9965.EPI-24-0306","url":null,"abstract":"<p><strong>Background: </strong>Body composition may be related to survival in patients with clear-cell renal cell carcinoma (ccRCC), but studies have not simultaneously considered adipose and muscle tissue quantity and radiodensity.</p><p><strong>Methods: </strong>We analyzed data from 1,022 patients with ccRCC who underwent nephrectomy between 2000 and 2020 at Memorial Sloan Kettering Cancer Center. Skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue indexes (cm2/m2) and radiodensities [Hounsfield units (HU)] were assessed from noncontrast presurgical CT scans; clinical and demographic characteristics were available from the time of surgery. HRs and confidence intervals were estimated for overall (OS) and disease-free survival (DFS) through March 2023 in multivariable models that simultaneously accounted for all body composition measures.</p><p><strong>Results: </strong>The median age of the patients was 58 years, 69% were male, and 90% were White. There were 169 OS events over 8,392 person-years and 253 DFS events over 7,753 person-years of follow-up. In adjusted analyses, poor OS was associated with lower skeletal muscle radiodensity [-10 HU, HR (95% confidence interval), 1.37 (1.05-1.77)] and greater visceral adipose tissue radiodensity [+10 HU, 1.66 (1.06-2.59)], with similar findings for DFS. Poor survival was also associated with greater visceral adipose tissue index [+40 cm2/m2, OS: 1.32 (0.97, 1.79); DFS: 1.33 (1.04, 1.71)]. Associations with skeletal muscle radiodensity were limited to patients with stage 1/2 disease.</p><p><strong>Conclusions: </strong>Radiodensities of skeletal muscle and visceral adipose tissues may be novel presurgical prognostic factors for patients with ccRCC.</p><p><strong>Impact: </strong>The findings underscore the importance of evaluating the full range of body composition features simultaneously in multivariable models.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1375-1382"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Cancer: Progress and Priorities. 肝癌:进展与优先事项。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0686
Katherine A McGlynn, Jessica L Petrick, John D Groopman

Liver cancer, the sixth most frequently occurring cancer in the world and the third most common cause of cancer mortality, has wide geographical variation in both incidence and mortality rates. At the end of the 20th century, incidence rates began declining in some high-rate areas and increasing in some lower-rate areas. These trends were undoubtedly driven by the shifting contributions of both well-established and more novel risk factors. While notable strides have been made in combating some major risk factors, such as hepatitis B virus and hepatitis C virus, the emergence of metabolic conditions as important drivers of liver cancer risk indicates that much work remains to be done in prevention. As liver cancer is strongly associated with economic and social deprivation, research, early-diagnosis, and treatment among disadvantaged populations are of paramount importance.

肝癌是世界上发病率第六高的癌症,也是导致癌症死亡的第三大常见病因,其发病率和死亡率的地域差异很大。20 世纪末,一些高发病率地区的发病率开始下降,而一些低发病率地区的发病率则开始上升。毫无疑问,这些趋势是由已确立的风险因素和较新的风险因素共同作用的结果。虽然在应对乙肝病毒和丙肝病毒等一些主要风险因素方面取得了显著进展,但新陈代谢条件成为肝癌风险的重要驱动因素,这表明在预防方面仍有许多工作要做。由于肝癌与经济和社会贫困密切相关,因此对弱势群体进行研究、早期诊断和治疗至关重要。
{"title":"Liver Cancer: Progress and Priorities.","authors":"Katherine A McGlynn, Jessica L Petrick, John D Groopman","doi":"10.1158/1055-9965.EPI-24-0686","DOIUrl":"10.1158/1055-9965.EPI-24-0686","url":null,"abstract":"<p><p>Liver cancer, the sixth most frequently occurring cancer in the world and the third most common cause of cancer mortality, has wide geographical variation in both incidence and mortality rates. At the end of the 20th century, incidence rates began declining in some high-rate areas and increasing in some lower-rate areas. These trends were undoubtedly driven by the shifting contributions of both well-established and more novel risk factors. While notable strides have been made in combating some major risk factors, such as hepatitis B virus and hepatitis C virus, the emergence of metabolic conditions as important drivers of liver cancer risk indicates that much work remains to be done in prevention. As liver cancer is strongly associated with economic and social deprivation, research, early-diagnosis, and treatment among disadvantaged populations are of paramount importance.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"33 10","pages":"1261-1272"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are women's breast cancer risk appraisals in line with updated clinical risk estimates communicated? Results from a UK Family History Risk and Prevention Clinic. 妇女的乳腺癌风险评估是否与最新的临床风险评估一致?英国家族史风险与预防诊所的研究结果。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0581
Victoria G Woof, Anthony Howell, Lynne Fox, Lorna McWilliams, D Gareth R Evans, David P French

Background: The incorporation of breast density and a polygenic risk score (PRS) into breast cancer risk prediction models can alter previously communicated risk estimates. Previous research finds that risk communication does not usually change personal risk appraisals. This study aimed to examine how women from the Family History Risk (FH-Risk) study appraise their breast cancer risk following communication of an updated risk estimate.

Methods: In the FH-Risk study 323 women attended a consultation to receive an updated breast cancer risk estimate. A subset (n=190) completed a questionnaire, assessing their subjective breast cancer risk appraisals, satisfaction with the information provided and cancer related worry. One hundred and three were notified of a decrease risk, 34 an increase and 53 an unchanged risk.

Results: Women's subjective risk appraisals were in line with the updated risk estimates provided, with age, a PRS and breast density explaining most of the variance in these appraisals. Those notified of an increased risk demonstrated higher subjective risk perceptions compared to those whose risk remained unchanged or decreased.

Conclusions: Women's subjective breast cancer risk appraisals are amenable to change following updated risk feedback, with new information breast density and a PRS accepted and integrated into existing risk appraisals. Trust in the service, the analogies and visual communication strategies used may have positively influenced the integration of this new information.

Impact: Further research is warranted to assess whether similar patterns emerge for other illnesses and in different clinical contexts to determine the best strategies for communicating updated risk estimates.

背景:将乳房密度和多基因风险评分(PRS)纳入乳腺癌风险预测模型可能会改变之前通报的风险估计值。以往的研究发现,风险交流通常不会改变个人的风险评估。本研究旨在探讨家族史风险(FH-Risk)研究中的女性在获悉最新风险评估后如何评估其乳腺癌风险:在 "家族史风险 "研究中,有 323 名妇女参加了咨询会,接受了最新的乳腺癌风险评估。其中一部分人(190 人)填写了一份问卷,评估她们对乳腺癌风险的主观评价、对所提供信息的满意度以及与癌症有关的担忧。有 103 名妇女被告知风险降低,34 名妇女被告知风险升高,53 名妇女被告知风险不变:结果:妇女的主观风险评估与提供的最新风险估计值一致,年龄、PRS 和乳房密度解释了这些评估中的大部分差异。与风险保持不变或降低的妇女相比,那些被告知风险增加的妇女表现出更高的主观风险感知:结论:妇女对乳腺癌风险的主观评估可根据最新的风险反馈进行改变,新信息乳腺密度和 PRS 可被接受并纳入现有的风险评估中。对服务的信任、所使用的类比和视觉交流策略可能会对这些新信息的整合产生积极影响:影响:有必要开展进一步研究,以评估其他疾病和不同临床情况下是否会出现类似的模式,从而确定传达最新风险评估的最佳策略。
{"title":"Are women's breast cancer risk appraisals in line with updated clinical risk estimates communicated? Results from a UK Family History Risk and Prevention Clinic.","authors":"Victoria G Woof, Anthony Howell, Lynne Fox, Lorna McWilliams, D Gareth R Evans, David P French","doi":"10.1158/1055-9965.EPI-24-0581","DOIUrl":"10.1158/1055-9965.EPI-24-0581","url":null,"abstract":"<p><strong>Background: </strong>The incorporation of breast density and a polygenic risk score (PRS) into breast cancer risk prediction models can alter previously communicated risk estimates. Previous research finds that risk communication does not usually change personal risk appraisals. This study aimed to examine how women from the Family History Risk (FH-Risk) study appraise their breast cancer risk following communication of an updated risk estimate.</p><p><strong>Methods: </strong>In the FH-Risk study 323 women attended a consultation to receive an updated breast cancer risk estimate. A subset (n=190) completed a questionnaire, assessing their subjective breast cancer risk appraisals, satisfaction with the information provided and cancer related worry. One hundred and three were notified of a decrease risk, 34 an increase and 53 an unchanged risk.</p><p><strong>Results: </strong>Women's subjective risk appraisals were in line with the updated risk estimates provided, with age, a PRS and breast density explaining most of the variance in these appraisals. Those notified of an increased risk demonstrated higher subjective risk perceptions compared to those whose risk remained unchanged or decreased.</p><p><strong>Conclusions: </strong>Women's subjective breast cancer risk appraisals are amenable to change following updated risk feedback, with new information breast density and a PRS accepted and integrated into existing risk appraisals. Trust in the service, the analogies and visual communication strategies used may have positively influenced the integration of this new information.</p><p><strong>Impact: </strong>Further research is warranted to assess whether similar patterns emerge for other illnesses and in different clinical contexts to determine the best strategies for communicating updated risk estimates.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Magnesium Level and Risk of Hepatocellular Carcinoma in a Prospective Liver Cirrhosis Cohort. 前瞻性肝硬化队列中的血镁水平与肝细胞癌风险。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1158/1055-9965.EPI-24-0327
Xinyuan Zhang, Longgang Zhao, Qi Dai, Tao Hou, Christopher J Danford, Michelle Lai, Xuehong Zhang

Background: Higher magnesium intake was linked to a lower risk of hepatocellular carcinoma (HCC). However, the relationship between blood magnesium level and HCC has not been fully characterized, especially among patients with liver cirrhosis who are at a higher risk for HCC.

Methods: In the Mass General Brigham Biobank, we developed a new prospective cohort of 1,430 patients with liver cirrhosis without liver cancer history using the validated International Classification of Diseases codes. We used Cox proportional hazards models to generate hazard ratios (HRs) with 95% confidence intervals (CI) for incident HCC and used generalized estimating equations to compare changes in liver biomarkers according to baseline blood magnesium, adjusting for age, sex, race, lifestyles, body mass index, type 2 diabetes, model for end-stage liver disease score, and hepatitis infection.

Results: During a median follow-up period of 4.26 years, 109 patients developed HCC. Magnesium deficiency (<1.70 mg/dL; N = 158) was associated with a higher risk of HCC (HR = 1.93; 95% CI, 1.12-3.30) compared with magnesium sufficiency (≥1.70 mg/dL; N = 1282). This association remained robust in the 1-year lag analysis (HR = 2.18; 95% CI, 1.11-4.28) and in sensitivity analysis excluding patients with alcoholic liver disease (HR = 2.41; 95% CI, 1.23-4.74). Magnesium in the lowest quartile was associated with a faster increase in alanine transaminase (β = 4.35; 95% CI, 1.06-7.63), aspartate aminotransferase (β = 6.46; 95% CI, 0.28-12.6), direct bilirubin (β = 0.18; 95% CI, 0.01-0.35), and total bilirubin (β = 0.21; 95% CI, 0.03-0.39), compared with the highest quartile.

Conclusions: Lower blood magnesium level is associated with higher HCC risk and unfavorable liver biomarker changes.

Impact: If confirmed, our findings may potentially enable better identification of high-risk patients for HCC and inform better management strategies for liver cirrhosis.

背景:较高的镁摄入量与较低的肝细胞癌(HCC)风险有关。然而,血镁水平与 HCC 之间的关系尚未完全定性,尤其是在 HCC 风险较高的肝硬化患者中:在麻省总医院布里格姆生物库中,我们使用有效的国际疾病分类代码建立了一个新的前瞻性队列,其中包括 1460 名无肝癌病史的肝硬化患者。我们使用 Cox 比例危险模型得出了发生 HCC 的危险比(HRs)及 95% 置信区间(CIs),并使用广义估计方程比较了肝脏生物标志物随基线血镁变化的情况,同时调整了年龄、性别、种族、生活方式、体重指数、2 型糖尿病、终末期肝病评分模型和肝炎感染等因素:在中位 4.26 年的随访期间,109 人罹患 HCC。镁缺乏血镁水平较低与较高的 HCC 风险和不利的肝脏生物标志物变化有关:如果得到证实,我们的研究结果可能有助于更好地识别HCC高风险患者,并为肝硬化的更好管理策略提供依据。
{"title":"Blood Magnesium Level and Risk of Hepatocellular Carcinoma in a Prospective Liver Cirrhosis Cohort.","authors":"Xinyuan Zhang, Longgang Zhao, Qi Dai, Tao Hou, Christopher J Danford, Michelle Lai, Xuehong Zhang","doi":"10.1158/1055-9965.EPI-24-0327","DOIUrl":"10.1158/1055-9965.EPI-24-0327","url":null,"abstract":"<p><strong>Background: </strong>Higher magnesium intake was linked to a lower risk of hepatocellular carcinoma (HCC). However, the relationship between blood magnesium level and HCC has not been fully characterized, especially among patients with liver cirrhosis who are at a higher risk for HCC.</p><p><strong>Methods: </strong>In the Mass General Brigham Biobank, we developed a new prospective cohort of 1,430 patients with liver cirrhosis without liver cancer history using the validated International Classification of Diseases codes. We used Cox proportional hazards models to generate hazard ratios (HRs) with 95% confidence intervals (CI) for incident HCC and used generalized estimating equations to compare changes in liver biomarkers according to baseline blood magnesium, adjusting for age, sex, race, lifestyles, body mass index, type 2 diabetes, model for end-stage liver disease score, and hepatitis infection.</p><p><strong>Results: </strong>During a median follow-up period of 4.26 years, 109 patients developed HCC. Magnesium deficiency (<1.70 mg/dL; N = 158) was associated with a higher risk of HCC (HR = 1.93; 95% CI, 1.12-3.30) compared with magnesium sufficiency (≥1.70 mg/dL; N = 1282). This association remained robust in the 1-year lag analysis (HR = 2.18; 95% CI, 1.11-4.28) and in sensitivity analysis excluding patients with alcoholic liver disease (HR = 2.41; 95% CI, 1.23-4.74). Magnesium in the lowest quartile was associated with a faster increase in alanine transaminase (β = 4.35; 95% CI, 1.06-7.63), aspartate aminotransferase (β = 6.46; 95% CI, 0.28-12.6), direct bilirubin (β = 0.18; 95% CI, 0.01-0.35), and total bilirubin (β = 0.21; 95% CI, 0.03-0.39), compared with the highest quartile.</p><p><strong>Conclusions: </strong>Lower blood magnesium level is associated with higher HCC risk and unfavorable liver biomarker changes.</p><p><strong>Impact: </strong>If confirmed, our findings may potentially enable better identification of high-risk patients for HCC and inform better management strategies for liver cirrhosis.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1368-1374"},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Epidemiology Biomarkers & Prevention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1